Acelity Buys Autologous Fat Grafting System From The GID Group

San Antonio, Texas-based Acelity has acquired the rights to the Revolve system, a fat processing technology used in both reconstructive and cosmetic procedures to facilitate high-volume, autologous fat grafting, from The GID Group Inc. LifeCell Corporation, an Acelity company, has held exclusive rights to distribute the Revolve system in the United States and Canada since 2013. This new agreement provides LifeCell with worldwide rights for development, manufacturing and commercialization of the device.

“We are looking forward to working with the plastic surgery community to further develop the Revolve system and bring its clinical and economic benefits to patients around the world,” said Ron Silverman, M.D., chief medical officer of Acelity. “It aligns with our strategy of broadening our regenerative medicine portfolio of products for plastic surgeons by providing solutions that go beyond acellular dermal matrix procedures.”

Fat grafting is used in a minimally-invasive procedure that removes fat from one part of the body and grafts it to another. The technique is being used more frequently in both reconstructive and cosmetic procedures because it often provides more natural solutions. The Revolve system is designed to yield rapid, reliable results in high-volume procedures through the use of a simple, closed system that controls critical variables in the procedure.

“Fat grafting use among plastic surgeons is growing, but there remain many opportunities to improve the way it is performed, particularly in large volume breast procedures,” said Adam Katz, M.D., plastic surgeon and co-founder of The GID Group. “We believe Acelity is the ideal company to further develop this technology and create new ways to deliver the benefits of fat grafting to patients worldwide.”

Acelity is a wound care and regenerative medicine company.